Diabetes is on the rise across the globe as reported in the most recent 8th edition of the International Diabetes Federation (IDF) Diabetes Atlas 2017. As Diabetes is a lifestyle disease, it can be prevented by adopting appropriate lifestyle. This is what the evidence from studies conducted in the USA, Finland, China, India and Japan have proved. However, the pharma industry has been investing on R&D and launching new products but needs much more. From January 2019 to October 31, 2019, the US FDA has approved three products for type 2 diabetes (two drugs Rybelsus and Victoza from Novo Nordisk and one drug – Farxiga from AstraZeneca).
